Enrichment of Short Nucleic Acid Fragments in Sequencing Library Preparation
Methods for preparing enriched sequencing libraries from test samples that contain double-stranded deoxyribonucleic acid (dsDNA) are provided.
1 . A method for preparing an enriched sequencing library, the method comprising:
(a) obtaining a test sample comprising a plurality of double-stranded deoxyribonucleic acid (dsDNA) fragments;
(b) ligating double-strand DNA (dsDNA) adapters to both ends of the dsDNA fragments to generate a plurality of adapter-fragment constructs, wherein the dsDNA adapter: (i) comprises a first strand and a second strand, or (ii) are shorter than 50 nucleotides in length;
(c) amplifying the adapter-fragment constructs to generate a sequencing library; and
(d) enriching the sequencing library for adapter-fragment constructs derived from dsDNA fragments 150 bp or less in length to generate an enriched sequencing library, wherein the enrichment comprises enrichment for genetic regions or genetic fragments of interest.
2 . The method of claim 1 , wherein the genetic regions or genetic fragments of interest comprise cancer-related genes or gene fragments of interest.
3 . The method of claim 1 , wherein the double-stranded DNA (dsDNA) fragments comprise cell-free DNA (cfDNA) fragments.
4 . The method of claim 1 , wherein the test sample is selected from: (i) whole blood, a blood fraction, plasma, serum, urine, fecal, saliva, a tissue biopsy, pleural fluid, pericardial fluid, cerebral spinal fluid, peritoneal fluid, or any combination thereof; and/or (ii) a plasma sample obtained from a patient known to have, or suspected of having cancer, optionally wherein the test sample comprises nucleic acids originating from healthy cells and from cancer cells.
5 . The method of claim 1 , wherein enrichment for genetic regions or genetic fragments of interest comprise hybrid capture.
6 . The method of claim 1 , wherein the dsDNA fragments are purified from the test sample, prior to ligation step (b).
7 . The method of claim 1 , wherein the dsDNA fragments are enriched using gel electrophoresis or size selection beads.
8 . The method of claim 7 , wherein the size selection beads are utilized to enrich for dsDNA fragments, or adapter-fragment constructs derived from dsDNA fragments, having: (i) a length of less than 140 bp; or (ii) a length that ranges from 60 bp to 140 bp.
9 . The method of claim 1 , wherein the enriched sequencing library is sequenced to generate a plurality of sequence reads.
10 . The method of claim 9 , wherein the sequence reads are identified based on alignment of the sequence reads to a reference genome, or a portion of a reference genome, or based on a de novo assembly.
11 . The method of claim 9 , wherein the plurality of sequence reads are used for detecting cancer, screening for cancer, determining cancer stage or status, monitoring cancer progression, and/or determining a cancer classification.
12 . The method of claim 11 , wherein monitoring cancer progression further comprises monitoring disease progression, monitoring therapy, or monitoring cancer growth.
13 . The method of claim 11 , wherein the cancer classification comprises determining cancer type and/or cancer tissue of origin.
14 . The method of claim 11 , wherein the cancer comprises a carcinoma, a sarcoma, a myeloma, a leukemia, a lymphoma, a blastoma, a germ cell tumor, or any combination thereof.
15 . The method of claim 14 , wherein the cancer is selected from the group consisting of: adenocarcinoma, squamous cell carcinoma, small cell lung, non-small-cell lung, nasopharyngeal, colorectal, anal, liver, urinary bladder, cervical, testicular, ovarian, gastric, esophageal, head-and-neck, pancreatic, prostate, renal, thyroid, melanoma, breast carcinoma, osteosarcoma, chondrosarcoma, leiomyosarcoma, rhabdomyosarcoma, mesothelial sarcoma (mesothelioma), fibrosarcoma, angiosarcoma, liposarcoma, glioma, astrocytoma, myelogenous, granulocytic, lymphatic, lymphocytic, lymphoblastic leukemia, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, or any combination thereof.
16 . The method of claim 9 , wherein the plurality of sequencing reads are analyzed to identify methylation profiles indicative of the presence or absence of cancer.
17 . The method of claim 9 , wherein the plurality of sequencing reads are analyzed to identify one or more mutational signatures indicative of the presence or absence of cancer.
18 . The method of claim 9 , wherein the plurality of sequencing reads are analyzed to assess the fractional contribution of different tissues to a DNA mixture.
19 . The method of claim 9 , wherein the plurality of sequencing reads are utilized to analyze nucleic acid fragmentation patterns for the detection and/or classification of cancer.